Macrocyclic RIP2 Kinase Inhibitors Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases associated with RIP2 kinase activity, such as Crohn's disease and sarcoidosis, are non-specific and have significant side effects, with existing kinase inhibitors like Gefitinib and Erlotinib being non-selective and not primarily targeting RIP2 kinase activity effectively.
Innovation Solution
Development of macrocyclic pyrazolopyrimidines and imidazopyridazines as selective RIP2 kinase inhibitors to block pro-inflammatory signaling pathways, providing a therapeutic benefit for RIP2-kinase associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific immunologic inhibition (e.g., corticosteroids) or specific cytokine inhibition (e.g., anti-TNF therapies) is used to treat inflammatory diseases, then therapeutic effect is achieved, but significant side effects occur and treatment is not ideal due to lack of efficacy in all patients
Solution Approach 1:
The invention targets a specific kinase (RIP2) within the broader inflammatory signaling pathway, segmenting the treatment approach from broad immunosuppression to focused kinase inhibition. This selective targeting of RIP2 kinase activity in the NOD1/2 signaling pathway achieves therapeutic effect while avoiding the side effects of non-specific immunologic inhibition
Solution Approach 2:
The macrocyclic compounds exhibit local quality by specifically inhibiting RIP2 kinase activity at the molecular level while leaving other cellular functions intact. This localized action at the RIP2 kinase site provides selective therapeutic effect without the systemic side effects of corticosteroids or anti-TNF therapies
2Reliability
If existing kinase inhibitors like Gefitinib and Erlotinib are used, then RIP2 kinase activity is inhibited, but the inhibitors are non-selective and do not primarily target RIP2 kinase activity effectively
Solution Approach 1:
The macrocyclic compounds are designed with local quality features that specifically recognize and bind to the RIP2 kinase active site. The molecular structure is optimized for selective interaction with RIP2, providing high selectivity and effective primary targeting of RIP2 kinase activity unlike non-selective inhibitors
Solution Approach 2:
The invention changes the chemical and structural parameters of the kinase inhibitor to achieve optimal selectivity for RIP2. The macrocyclic structure and specific substituent patterns are designed to match the unique features of the RIP2 kinase binding site, enhancing selectivity and primary targeting capability
Data Source
AI summary
The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.